Male sexual function involves complex interactions among psychosocial, neurogenic, vascular, and endocrine factors that contribute to initiation of erection culminating in ejaculation and orgasm [1, 2]. Male sexual dysfunction occurs with disruption of any of these processes and encompasses decreased libido, erectile dysfunction (ED), ejaculation disorders, and orgasmic dysfunction [3]. ED receives the most attention and concordantly is the most well-studied and understood by patients and providers [4]. Compared to ED where reliable and well-studied treatments are available, there remains a paucity of standardized treatments for men with ejaculatory and/or orgasmic dysfunction. There are extensive well-studied treatments for ED including multiple phosphodiesterase-5 inhibitors, vacuum devices, self-injectable drugs, and penile prosthesis; meanwhile, there are no FDA approved pharmacotherapies or invasive non-pharmacological interventions approved for delayed orgasm (DO) [5, 6]. However, orgasm and ejaculation represent fundamental aspects of male sexual function, and ejaculatory and orgasmic dysfunction are highly prevalent and tremendously impact on quality of life [7,8,9].

Male orgasmic dysfunction can be dichotomized as two ends of a spectrum: premature ejaculation (PE) versus DO and anorgasmia (AO) [10, 11]. Though ejaculation and orgasm are distinct events, they occur simultaneously in men and often are used interchangeably in the literature when discussing delayed ejaculation (DE) vs. DO [6]. In this review, we specifically focus on summarizing the current knowledge regarding the epidemiology, pathophysiology, diagnosis, and treatment of DO/AO. Recently, the American Urological Association (AUA) released the Disorders of Ejaculation guidelines that we will also highlight [6].


In this narrative review, the PubMed database was used to identify articles using the search terms: male sexual dysfunction, male delayed orgasm, delayed ejaculation, anorgasmia, male orgasm, ejaculation. There was no limitation on date range. Clinical trials, case studies, abstracts, review articles, and questionnaire-based surveys were included. Only studies published in English were considered.

Anatomy and physiology of male ejaculation and orgasm

It is important to realize that ejaculation and orgasm are two separate processes as orgasm can occur without ejaculation. However, as aforementioned, studies surrounding delay in these processes often use the terms DE and DO interchangeably.

Male ejaculation can be divided into two distinct phases: emission and expulsion [12]. The first phase of emission is characterized by passage of seminal fluid from the prostate, seminal vesicles, and vas deferens into the posterior urethra [13]. This occurs concomitantly with contraction of the internal urethral sphincter, which closes the bladder neck to prevent retrograde passage of semen [13]. This process is dependent on smooth muscle contraction and autonomic innervation from the pelvic plexus [14]. Stimuli from sensory receptors at the glans integrate at the spinal level to stimulate emission [14]. Expulsion, also known as antegrade ejaculation, is the second phase of ejaculation and is characterized by the passage of seminal fluid from the posterior urethra to the external urethral meatus [15]. This is regulated by contractions of striated pelvic floor muscles [15,16,17].

Male orgasm occurs secondary to pressure buildup within the posterior urethra due to closure of the bladder neck and external urethral sphincter and contraction of the periurethral musculature [13].

The anatomy of orgasm has been delineated by several functional neuroimaging studies; a meta-analysis demonstrated that in both heterosexual and homosexual men, sites of cortical activation include the lateral occipitotemporal, inferotemporal, parietal, orbitofrontal, medial prefrontal, insular, anterior cingulate, and frontal premotor cortices [18]. Likewise, positron emission tomography (PET) studies concordantly demonstrate increased activity in the occipitotemporal lobes, anterior cingulate, insular cortices, bilateral substantia nigra, right pons, left dentate cerebellar nucleus, and left lateral midbrain during orgasm [19]. Conversely, there is a decrease in the regional cerebral blood flow across the prefrontal cortex during ejaculation [18]. Flannigan et al. observed increased activation in the right fusiform gyrus among men with DO compared to controls; using the Allen Atlas of Human Brain Expression, corresponding neurotransmitter receptors to this region include adenosine receptors, muscarinic and nicotinic cholinergic receptors, cannabinoid receptors, and dopamine receptors [20]. These receptors serve as potential targets for novel pharmacotherapies.

Definition of DO/AO

Although most definitions are similar, there is no standardized definition for DO. The AUA guidelines on disorders of ejaculation recognize that there are multiple terms to refer to delays in ejaculations and/or orgasm including DE and DO [6]. Though it is acknowledged that ejaculation and orgasm are separate entities, the term DE is often used to refer to both difficulties with ejaculation and orgasm. Additionally, the AUA guidelines consider AO to be “the condition in which sexual climax cannot be reached via any means of stimulation” [6].

The Diagnostic and Statistical Manual of Mental Disorders 5th Edition (DSM-V) states that “distressing difficulties with orgasm in men would be considered under delayed ejaculation,” which is defined as a marked delay in ejaculation or a marked infrequency of absence of ejaculation on 75–100% of all occasions of partnered sexual activity without the individual desiring delay, persisting for at least 6 months, and causing significant distress to the individual [11]. DSM-V does not provide a definition for AO [11].

The International Classification of Diseases (ICD)-11 defines DE as an inability to achieve ejaculation or an excessive or increased latency of ejaculation, despite adequate sexual stimulation and the desire to ejaculate [21]. The ICD-11 defines AO as “the absence or marked infrequency of the orgasm experience or markedly diminished intensity of orgasmic sensations,” though states that AO in men would be encompassed in the diagnosis of DE [21]. For both DO and AO, these patterns of orgasmic dysfunction have occurred episodically or persistently over a period of at least several months and is associated with clinically significant distress [21]. AO is often considered to be the most extreme presentation of DO and thus has similar etiology and treatment options.

DO can also be further categorized as lifelong/primary (present since first sexual encounter) versus acquired/secondary (prior normal orgasm able to be achieved) and generalized (always present) versus situational (only present due to certain stimuli, with certain partners, or in certain situations) [22]. The Third International Consultation on Sexual Medicine defines the time threshold for DO based on studies examining mean intravaginal ejaculation latency time (IELT; defined as the time between the start of vaginal intromission and the start of intravaginal ejaculation) [23]. Waldinger et al. measured stopwatch-assessed IELT among men from the Netherlands, United Kingdom, Spain, Turkey, and the United States and determined that median IELT is 5.4 min (range: 0.55–44.1 min) [24]. Thus, it has been extrapolated that IELT for DO would be 2 standard deviations above, equivalent to an estimated 20–25 min [22].


Kinsey et al. found that on 15 out of 10,000 participants had primary AO [25] while Nathan et al. found the prevalence of inhibited male orgasm to be 5% [26]. DO and DE are used interchangeably in the literature, the true prevalence of AO and DO is difficult to extrapolate since difficulties with orgasm and ejaculation are often not separated in studies. Corona et al. evaluated 2652 men and asked patients about difficulty with ejaculation and climax. They observed a 7.3% (n = 194) prevalence of DE and/or DO [10]. In a separate study, the same author group evaluated the prevalence of sexual dysfunction among 2437 men with mean age 51.9 years and reported a 4.4% rate of DE and/or DO [27]. However, it is postulated that the prevalence of DO is likely higher as embarrassment may preclude men from seeking treatment or discussing this condition with their providers [28].

Pathophysiology of DO

Several etiologies have been identified in the pathophysiology of DO, owing to the multifactorial, complex nature of the disorder. The most common etiologies include selective serotonin reuptake inhibitors (SSRI; 42%), psychogenic (28%), low testosterone (T; 21%), abnormal penile sensation (7%), and penile hyperstimulation (2%) [29].


Given the fundamental role of hormonal regulation in the physiology of orgasm, multiple endocrinopathies have been identified in patients with DO. Corona et al. compared T levels among 2437 men (mean age 51.9 ± 13.0 years) with PE or DO versus those without ejaculatory dysfunction and demonstrated lower total and free T levels among patients with DO [27]. Patients with DO had higher prevalence of testosterone deficiency when compared to patients with PE (26 vs. 12%, respectively) [27]. The varied prevalence of testosterone deficiency among patients with PE and DO compared to the control group remained statistically significant even when controlling for age (HR = 0.75 [0.57–0.99] and 1.83 [1.14–3.94], respectively; both p < 0.05) [27].

Hyperprolactinemia also leads to DO as increased levels of prolactin (PRL) result in suppression of T production [30]. Hyperprolactinemia can be defined as mild (>420 mU/L or 20 ng/mL) versus severe (>735 mU/L or 35 ng/mL) [30]. It has been shown that PRL levels progressively increase when comparing men with PE versus no ejaculatory dysfunction versus DO respectively [10].

Likewise, aberrant thyroid stimulating hormone (TSH) levels have been associated with orgasmic dysfunction. Hyperthyroid patients often experience PE whereas hypothyroid patients often experience DO. A multicenter prospective study of 48 men (n = 34 hyperthyroid, n = 14 hypothyroid) demonstrated that IELT significantly improved after normalization of TSH levels [31]. Among hyperthyroid men, IELT doubled from 2.4 min to 4.0 min after treatment, whereas IELT significantly decreased from 22 to 7 min in hypothyroid men [31].


The most common medications implicated in the pathogenesis of DO include antidepressants and antipsychotics (Table 1) [32,33,34,35,36,37,38]. The underlying mechanism of SSRI-induced DO is that serotoninergic inputs from the dorsal raphe nucleus stimulate PRL-releasing factors in the paraventricular nucleus [39], resulting in hyperprolactinemia and subsequent suppression of T production as described above [14]. Furthermore, SSRIs are associated with a twofold risk of lower libido [40]. The rate of orgasmic dysfunction at 8 weeks following initiation of antidepressant therapy are as follows: escitalopram (30%), bupropion (15%), placebo (9%) [41].

Table 1 Medications associated with delayed orgasm or anorgasmia.


Psychogenic DO results from feelings of fear, anxiety, hostility, relationship difficulties associated with sexual intercourse and encounters [42]. Common triggers include childhood sexual abuse, sexual trauma, repressive sexual education or religious beliefs, general anxiety, and history of being widowed or divorced [43].

One specific scenario that has been studied in patients with situational DO is timed intercourse for fertility treatment [44]. Byun et al. demonstrated a 42.8% (n = 188) and 5.92% (n = 26) rate of ED and DO respectively among 439 men undergoing timed intercourse. The Beck Anxiety Inventory, a standardized measure of anxiety level, was significantly higher among men with DO (p < 0.001).

Penile hyperstimulation and sensation loss

Hyperstimulation of the penis is another factor that has been identified to contribute to DO. DO is significantly associated with higher masturbatory activity, decreased nighttime emissions, lower orgasm and intercourse satisfaction scores on the International Index of Erectile Function (IIEF) [45]. It is postulated that increased frequency of masturbation results in penile sensation loss which cascades into further increase of masturbation force. Consequently, this cycle results in DO during vaginal intercourse or orogenital stimulation as these processes are not able to replicate the necessary stimulation. Penile sensation loss has also been associated with increasing age [46].

Pelvic surgery patients

Orgasmic dysfunction has been demonstrated among patients who undergo pelvic surgeries [47]. Haney et al. reviewed the current literature on the prevalence of orgasmic dysfunction post-pelvic surgery and reported the following AO (AO) rates: radical prostatectomy (5–70%); radical cystectomy (33–63%); colorectal surgeries (0–52%) [47]. Preservation of orgasmic function is directly correlated to intraoperative nerve sparing; 90.7, 82.1, and 60.8% of men who underwent bilateral (n = 273/301), unilateral (46/56), and non-nerve sparing (n = 31/51) robotic-assisted laparoscopic prostatectomy reported preservation of orgasmic function post-operatively (p < 0.001) [48].

Patient evaluation and diagnosis of DO

Initial evaluation of a patient presenting with DO involves a thorough history and physical examination. This is the most important component of the patient’s evaluation. Critical components of the history intake include medical, surgical, psychiatric, sexual, social, and religious history. Medical history should include conditions associated with neuropathy, metabolic derangements, or trauma; surgical history should include the history of neurologic and pelvic procedures [49]. To date, no studies have identified an association between orgasmic dysfunction and recreational drug use, pornography use, or painful intercourse, but these still represent important components of the social history. Psychiatric history should delve into any stressors at home or work, history of infertility, sexual abuse or trauma, repressive sexual education or religious beliefs, and history of being widowed or divorced [22, 43].

Questioning regarding onset and duration of DO can also enable the clinician to decipher between lifelong/primary versus acquired/secondary DO and generalized versus situational DO [6]. The patient’s medication list should also be reviewed [6].

General physical examination is also performed to evaluate for any confounding organic conditions including metabolic disorders (obesity), decreased serum T (minimal body hair, muscular atrophy), and prior injuries (scars) [50,51,52]. Genitourinary examination should assess for undescended or solitary testicle as well as testicular atrophy [6].

Hormonal evaluation serves as the basis for laboratory testing when evaluating a patient with DO. The mainstay of hormonal laboratory testing is total and calculated bioavailable/free T, TSH, vitamin D, estradiol, and PRL [53, 54]. Baseline labs such as a basic metabolic panel (BMP), human immunodeficiency virus (HIV) testing, Hemoglobin A1c may also be assessed to evaluate for other underlying abnormalities as indicated by the patient’s history [51, 54, 55].

Adjunctive testing includes biothesiometry or pudendal somatosensory-evoked potential (SSEP) to evaluate for loss of penile sensitivity, sympathetic skin testing to assess sympathetic efferent flow to genital skin, and sacral reflex art testing to examine the motor and sensory branches of the pudendal nerves and the S2-4 nerve roots [22]. However, adjunctive testing is not routinely clinically indicated.

A proposed algorithm summarizing the evaluation of patients presenting with DO/AO is summarized in Fig. 1.

Fig. 1
figure 1

Proposed algorithm to approaching the patient who presents with DO/AO.

Treatment of DO

There is no standardized treatment plan for DO. Treatment plans are often multidisciplinary, involving urologists, primary care providers and mental health professionals to adequately address biopsychosocial factors. Before initiation of treatment, patients should be evaluated for organic causes. If DO is associated with SSRIs or other medications, patients should discuss medication adjustment with the prescribing physician [56]. As previously discussed, there are certain medications that have been associated with DO/AO (Table 1). Offending medications may be decreased or stopped altogether. An alternative medication with lower risk of orgasmic dysfunction may be recommended as a substitute. Additionally, medications with a shorter half-life may also be preferable if a patient is experiencing sexual side effects [6].

Testosterone replacement is indicated for men with testosterone deficiency in accordance with available guidelines [57, 58]. In men with DO as their primary symptom of testosterone deficiency, we will consider a trial of testosterone therapy (injectables, topical, etc.). Anecdotally, we have used short-acting testosterone formulations that have rapid peak serum levels (intranasal testosterone gel) on demand (administered 1 h prior to sexual activity) in men with isolated DO and who do not desire to be on long-term testosterone therapy. ED can contribute to DO and thus should be treated with phosphodiesterase-5 inhibitors, self-injections, and/or vacuum devices [56]. In patients with hyperprolactinemia or thyroid dysfunction, appropriate referrals should be made.

Sex therapy

Psychosocial evaluation with a sex therapist is recommended for all patients [57]. Sex therapy may be used as a monotherapy although it is often used in conjunction with other forms of treatment. Therapy can include sex education, cognitive-behavioral therapy (CBT), couples therapy, psychodynamic exploration, and mindfulness [59]. The suggested approach differs depending on the root cause of the patient’s DO. Insufficient stimulation can occur due to diminished penile sensation both with a partner and during self-stimulation or due to a psychogenic etiology which is more likely to occur only with a partner. A sex therapy approach for these patients involves enhancing psychological arousal by using a vibrator or vigorous pelvic thrusting and addressing psychological factors that may be contributing to DO/AO [6]. Other patients prefer self-stimulation that impacts their ability to orgasm with a partner. For these patients, therapy is anchored on shifting focus from himself to his ability to receive pleasure from his partner [6]. For a subset of patients who experience a discrepancy between stimulation from a partner and personal masturbation techniques, masturbatory retraining can allow the patient to condition himself to respond to certain sexual stimuli that could ultimately be replicated with a partner [6].

Psychological intervention can also identify and address a patient’s psychological conflict with ejaculation that could stem from a variety of sources including discord between partners, fear that ejaculation will impregnate their partner, strife with relinquishing control, or phobia of success [60, 61]. Counselors may help the patient identify interpersonal factors or psychological barriers that are negatively impacting sexual function such as communication issues between partners or anxiety related to sexual activity [62]. Therapy should also aim to destigmatize the condition [62].

Exact rates of success are difficult to determine based on existing literature due to variability of therapy methods and lack of large-scale studies. Having a sex therapist available for referrals is an important consideration for providers since there can be issues with accessibility including long waiting lists and financial barriers since insurance coverage is variable. If such barriers to sex therapy exist, providers can begin by suggesting open discussions about sexual desires and preferences between the patient and their partner to facilitate treatment. Other low risk behavior modifications include erogenous zone stimulation, altering pressure and pace of penile stimulatory techniques, using vibrators, or incorporating roleplay. Modification should be based on the couple’s current sexual practice or positions, and the sexual desires and comfort levels of each partner [6].

Penile vibratory stimulation

If the patient reports decreased penile sensation and/or biothesiometry reveals abnormal penile sensitivity, penile vibratory stimulation (PVS) can be incorporated. During this treatment, a vibrator is applied to the frenulum of the penis for up to 10 min [63]. A study of 36 men with AO found that 72% of men who underwent PVS had restoration of orgasm on at least some occasions and these lasted at 6 month follow up [63]. However, large double-blind placebo-controlled studies are lacking and still needed to elucidate the true effectiveness of PVS. Although the current evidence is not conclusive to support the routine use of PVS, the AUA guidelines state that PVS may be recommended for interested patients given the minimal risk [6].


Though there are no drugs approved by the U.S. Food and Drug Administration (FDA) at this time due to the absence of conclusive data, several pharmacological therapies show promise in treatment of DO including cabergoline, bupropion, oxytocin, and recently amphetamine/dextroamphetamine (AdderallTM)22. A summary is provided in Table 2. Importantly, we should try to address any organic causes and/or sex therapy prior to or in conjunction with pharmacotherapy. Clinicians should work with prescribing providers to stop or decrease the dose of medications that may contribute to DO/AO [6].

Table 2 Summary table of pharmacotherapies for delayed orgasm or anorgasmia.

Cabergoline and bupropion are most commonly described in the literature. Cabergoline acts as a dopamine agonist at D2 receptors, resulting in decreased PRL levels. Dopamine has been observed to enhance sexual drive and orgasmic quality and facilitate penile erection, likely by increasing oxytocin release [13, 64, 65]. Acute decreases in PRL levels induced by dopamine agonists may also contribute to enhancing sexual function [66]. In a single-blind balanced crossover study of 10 healthy males, PRL levels were pharmacologically increased; following administration of cabergoline to decrease PRL, sexual drive and function significantly increased [66]. Similarly, a retrospective review of 131 men treated with cabergoline 0.5 mg twice a week at a single andrology clinic for DO/AO demonstrated that 66.7% (n = 87) of men reported subjective improvement in orgasm following therapy [67]. Duration of therapy (p = 0.03) and concomitant testosterone therapy (p = 0.02) were significantly associated with positive response to cabergoline treatment [67]. Furthermore, cabergoline was efficacious regardless of underlying etiology of DO. These studies suggest that acute PRL reduction modulates sexual function and cabergoline may serve as an effective treatment for DO. Prospective randomized trials are still needed.

Bupropion is an atypical antidepressant that inhibits reuptake of dopamine and norepinephrine. Compared to other antidepressants, bupropion has been shown to have lower rates of adverse sexual side effects and may even enhance sexual function in some patients [68]. In rats, bupropion increases contractile response to nerve stimulation in the vas deferens and the epididymal duct [69]. Modell et al. surveyed 107 patients on antidepressants and found that 77% of patients treated with bupropion reported improvement in at least one aspect of sexual functioning [68]. It has been posited that these pro-sexual effects are simply a result of the drug’s antidepressant activity in depressed patients; however, a study of 10 nondepressed men with DO showed that bupropion treatment resulted in significant improvement in sexual satisfaction, ability to achieve erection, and time to reaching orgasm, suggesting pro-sexual effects beyond its antidepressant activity [70]. Likewise, Adbel-Hamid et al. demonstrated a 25% decrease in mean ejaculation latency time and significantly improved orgasm and intercourse satisfaction among 19 men with DO who received bupropion-SR 150 mg daily for 2 months [71].

Oxytocin, a peptide released by the posterior pituitary gland, has been implicated in sexual function [72]. Oxytocin receptors have been identified throughout the male genital tract [73, 74]. Surges of oxytocin have also been observed during ejaculation and suppression of systemic oxytocin release with naloxone has resulted in decreased arousal and pleasure at orgasm [75,76,77]. Oxytocin has also been implicated in the contraction of the prostatic urethra, ejaculatory duct, and bladder neck [78]. There have been case reports of successful treatment of AO and improvement of sexual function with administration of intranasal oxytocin [79, 80]. Conversely, a prospective randomized study of 102 healthy men showed no significant difference in mean time to ejaculation between men who received intranasal oxytocin (n = 49, 10.24 min) compared to the control group (n = 53, 10.74 min; p = 0.53) [81]. Overall, the existing literature does not show conclusive evidence for the effects of oxytocin administration on sexual function and further studies must be done to clarify this relationship.

Some men with DO experience wandering thoughts during sexual activity and have difficulty concentrating, resulting in diminished sexual arousal. Thus, amphetamine/dextroamphetamine (AdderallTM), used in attention-deficit/hyperactivity disorder (ADHD), was trialed as treatment for DO [82]. Eight of 17 men with DO who were treated with Adderall reported improved sexual experience and 6 men experienced reduced orgasmic latency time (OLT). Among those with DO who saw improvement, mean OLT decreased by 72.3%. A case report showed that another ADHD drug, lisdexamfetamine dimesylate (VyvanseTM), was administered to a patient with neurogenic anejaculation and resulted in achievement of ejaculation with masturbation [83]. Additional evidence must be gathered to establish the effectiveness of these medications in DO.

Alpha-1 adrenergic receptors have been identified in the human vas deferens, seminal vesicle, and urethra [84,85,86]. Alpha-adrenergic receptor agonists including midodrine, imipramine, pseudoephedrine, and ephedrine have been used as treatments for DO. A systematic review of alpha-agonists showed that midodrine had the best rates of anejaculation reversal and the overall success rate of alpha-agonist treatment was 21% [87]. A study of midodrine in 185 men with spinal cord injury and anejaculation found that 64.6% of participants achieved either retrograde or antegrade ejaculation [88]. Large double-blind placebo-controlled studies are needed to truly evaluate these treatments for DO/AO.

There have been small trials using amantadine, cyproheptadine, yohimbine, buspirone, and bethanechol to treat antidepressant-induced sexual dysfunction. Shrivastava et al. successfully used amantadine to treat 6 men with DO secondary to paroxetine [89]. There are multiple case reports using cyproheptadine to treat DO or AO induced by antidepressants [90,91,92]. A clinical trial of 29 men with orgasmic dysfunction showed successful treatment with yohimbine, a selective competitive alpha-2 adrenergic receptor blocker, in 55% of men [93]. A clinical trial examining the effect of buspirone on sexual dysfunction in patients with depression found that of the 12 men who reported orgasm dysfunction at baseline, about half reported improved orgasm after treatment with buspirone [94]. Bethanechol, a muscarinic receptor agonist, has also been studied. A randomized, double-blind, placebo-controlled crossover trial of 12 men showed improvement in DO induced by antidepressants [95]. A larger sample size is needed to validate the effects of bethanechol in DO or AO. Additionally, more data must be gathered on the application of these medications to sexual dysfunction not induced by antidepressants. The existing literature provides insufficient evidence to recommend the use of these drugs in treatment of DO at this time.

Choosing the “Right” pharmacotherapy

A variety of oral pharmacotherapies have been studied for DO/AO, however as noted above most of the evidence is derived from small cohorts with incomplete characterization of other confounding factors. Choosing the right oral pharmacotherapy for a patient after addressing organic causes and considering sex therapy can be challenging. The specific treatment should be individualized and guided by an informed patient-provider discussion regarding outcomes and adverse effects. Other considerations include patient preferences such as the dosing regimen (on demand versus scheduled), cost and availability of the medication, and the provider’s level of comfort prescribing a specific medication and monitoring for side effects. The suspected etiology of DO/AO can also help guide treatment. Based on the available evidence, there is no “right” pharmacotherapy, and it is important to have an informed discussion and tailor an individualized treatment plan for men with DO/AO.

Invasive, non-pharmacological therapies

Some more invasive non-pharmacological therapies have been explored including intracavernosal injections of platelet rich plasma, pudendal nerves release, and surgical procedures. Given the lack of validated studies demonstrating their effectiveness and significant risks that come with invasive procedures, these interventions are not currently recommended as forms of treatment for DO/AO [6].


Orgasm and ejaculation represent fundamental aspects of male sexual function and disorders affecting these processes garner a tremendous impact on quality of life. DO and AO are prevalent among men and may be underreported due to patient embarrassment or discomfort. Given the complex and multifactorial nature of this condition, the most critical component of patient evaluation is gathering a thorough medical, surgical, and psychosocial history and performing a complete physical examination. Treatment options include addressing underlying organic causes and sex therapy. Though many promising pharmacotherapies have emerged, none are currently approved by the FDA for this indication. Future directions include developing a universal definition of DO and AO as well as a standardized pathway to achieve objective evaluation and diagnosis. Further studies elucidating the underlying molecular pathogenesis of orgasmic dysfunction can also lead to novel targeted pharmacotherapies.